z-logo
open-access-imgOpen Access
Disruptive technology and hemophilia care: The multiple impacts of emicizumab
Author(s) -
Hermans Cedric,
Makris Mike
Publication year - 2021
Publication title -
research and practice in thrombosis and haemostasis
Language(s) - English
Resource type - Journals
ISSN - 2475-0379
DOI - 10.1002/rth2.12508
Subject(s) - bispecific antibody , coagulation , medicine , intensive care medicine , immunology , antibody , monoclonal antibody
Emicizumab, a bispecific antibody mimicking the action of factor VIII (FVIII), is currently the first and only approved and increasingly accessible disruptive treatment option for hemophilia A, a disease so far mainly treated with frequent intravenous infusions of FVIII concentrates or bypassing agents in case of inhibitor development. Other disruptive treatments are expected to follow, such as agents that rebalance coagulation and gene therapy with the ambition of curing hemophilia. While these treatment options represent major achievements or expectations, their adoption and implementation should consider their multiple direct and indirect, immediate or delayed, consequences on hemophilia care globally. It is these multiple changes, present and future, already visible or hypothetical, that this article intends to review and explore.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here